Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Phosphatidylinositol 3′-Kinase Is a Critical Mediator of Interferon-γ-Induced Increases in Enteric Epithelial Permeability

Derek M. McKay, James L. Watson, Arthur Wang, Jackie Caldwell, David Prescott, Peter M. J. Ceponis, Vincenza Di Leo and Jun Lu
Journal of Pharmacology and Experimental Therapeutics March 2007, 320 (3) 1013-1022; DOI: https://doi.org/10.1124/jpet.106.113639
Derek M. McKay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James L. Watson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jackie Caldwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Prescott
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter M. J. Ceponis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincenza Di Leo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Lu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The epithelial lining of mucosal surfaces acts as a barrier to regulate the entry of antigen and pathogens. Nowhere is this function of the contiguous epithelium more important than in the gut, which is continually exposed to a huge antigenic load and, in the colon, an immense commensal microbiota. We assessed the intracellular signaling events that underlie interferon (IFN) γ-induced increases in epithelial permeability using monolayers of the human colonic T84 epithelial cell line. Confluent epithelial monolayers on semipermeable supports were treated with IFNγ (20 ng/ml), and barrier function was assessed 48 h later by measuring transepithelial electrical resistance (TER: reflects passive ion flux), fluxes of 51Cr-EDTA and horseradish peroxidase (HRP), and transcytosis of noninvasive, nonpathogenic Escherichia coli (strain HB101). Exposure to IFNγ decreased barrier function as assessed by all four markers. The phosphatidylinositol 3′-kinase (PI-3K) inhibitors, LY294002 [2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride] and wortmannin, did not affect baseline permeability characteristics but completely blocked the drop in TER, increased fluxes of 51Cr-EDTA and HRP, and significantly reduced E. coli transcytosis evoked by IFNγ. In addition, use of the pan-protein kinase C (PKC) inhibitor, bisindolylmaleimide I (5 μM), but not rottlerin (blocks PKCδ), partially ameliorated the drop in TER and inhibited increased E. coli transcytosis. Addition of the PI-3K and PKC inhibitors to epithelia 6 h after IFNγ exposure still prevented the increase in paracellular permeability but not E. coli transcytosis. Thus, IFNγ-induced increases in epithelial paracellular and transcellular permeability are critically dependent on PI-3K activity, which may represent an epithelial-specific target to treat immune-mediated loss of barrier function.

Footnotes

  • This work was supported by the Canadian Institutes of Health Research to DMM (Grant MT-13421 to D.M.M.). D.M.M. holds a Canada Research Chair (Tier 1) in Intestinal Immunophysiology in Health and Disease and is an Alberta Heritage Foundation for Medical Research scientist. J.L.W. was a recipient of a Canadian Institutes of Health Research studentship.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.106.113639.

  • ABBREVIATIONS: IFN, interferon; STAT, signal transducer and activator of transcription; PI-3K, phosphatidylinositol 3′-kinase; PKC, protein kinase C; IL, interleukin; LY294002, 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride; EGCG, (-)-epigallacatechin gallate; l-NAME, Nω-nitro-l-arginine methyl ester; NO, nitric oxide; NOS, nitric-oxide synthase; iNOS, inducible NOS; BIM, bisindolylmalemide I; l-NMMA, NG-monomethyl-l-arginine; l-NIL, N6-(1-iminoethyl)-lysine HCl; EPEC, enteropathogenic E. coli; LB, Luria Bertani broth; eGFP, enhanced green fluorescent protein; TER, transepithelial electrical resistance; HRP, horseradish peroxidase; PBS, phosphate-buffered saline; IRF, interferon-regulated factor; iNOS, inducible nitric oxide synthase; EMSA, electrophoretic mobility shift assay; LY, LY294002; PDK, phosphoinositide-dependent kinase; MAPK, mitogen-activated protein kinase; PIA, phosphatidylinositol analog; Akt, protein kinase B; SH5, Akt inhibitor II; API, Akt inhibitor V, Tricirbine; bp, base pair.

    • Received September 8, 2006.
    • Accepted December 15, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 3
1 Jun 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Phosphatidylinositol 3′-Kinase Is a Critical Mediator of Interferon-γ-Induced Increases in Enteric Epithelial Permeability
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Phosphatidylinositol 3′-Kinase Is a Critical Mediator of Interferon-γ-Induced Increases in Enteric Epithelial Permeability

Derek M. McKay, James L. Watson, Arthur Wang, Jackie Caldwell, David Prescott, Peter M. J. Ceponis, Vincenza Di Leo and Jun Lu
Journal of Pharmacology and Experimental Therapeutics March 1, 2007, 320 (3) 1013-1022; DOI: https://doi.org/10.1124/jpet.106.113639

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Phosphatidylinositol 3′-Kinase Is a Critical Mediator of Interferon-γ-Induced Increases in Enteric Epithelial Permeability

Derek M. McKay, James L. Watson, Arthur Wang, Jackie Caldwell, David Prescott, Peter M. J. Ceponis, Vincenza Di Leo and Jun Lu
Journal of Pharmacology and Experimental Therapeutics March 1, 2007, 320 (3) 1013-1022; DOI: https://doi.org/10.1124/jpet.106.113639
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ligustrazine Attenuates Liver Fibrosis
  • MK-5046, BRS-3 allosteric agonist
  • Renal Pharmacology of 8-Aminopurines
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics